First in Men Study: BIOMAG-I

NAActive, not recruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

April 27, 2020

Primary Completion Date

August 31, 2022

Study Completion Date

February 28, 2027

Conditions
Coronary Artery Disease
Interventions
DEVICE

Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold

Subjects with symptomatic coronary artery disease who qualify for percutaneous coronary intervention (PCI) will be treated with a sirolimus eluting resorbable coronary Magnesium scaffold

Trial Locations (14)

Unknown

Medizinische Universität Graz, Graz

Algemeen Ziekenhuis Middelheim, Antwerp

Ziekenhuis Oost-Limburg, Genk

UZ Leuven Gasthuisberg, Leuven

Segeberger Kliniken, Bad Segeberg

Herz-und Gefäßzentrum Oberallgäu-Kempten, Kempten

Johannes Wesling Klinikum Minden, Minden

Deutsches Herzzentrum, Münich

Rheinland Klinikum Lukaskrankenhaus Neuss, Neuss

Onze Lieve Vrouwe Gasthuis Amsterdam (OLVG), Amsterdam

Miedziowe Centrum Zdrowia SA, Lubin

Hospital Clinico San Carlos, Madrid

Lund University Hospital, Lund

University Hospital Geneva HUG, Geneva

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biotronik AG

INDUSTRY